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Down syndrome (DS) is the most common chromosomal abnormality in humans, 
caused by having three copies of human chromosome 21 (Hsa21). It is associated with a 
variety of features affecting almost every organ system, including the heart.  There is an 
especially high incidence of congenital heart defect (CHD) in DS, where 40 – 50% of 
affected individuals have a CHD. CHD is the most common congenital defect in live 
births.  The fact that half of those with DS have a normal heart suggests that additional 
genetic and environmental factors interact with trisomy 21 to cause CHD. Thus, people 
with trisomy 21 are sensitized to CHD.  
The Ts65Dn mouse model of DS was used as an analogous sensitized population 
to study the role of the Tbx5 gene in CHD.    Tbx5 is a modifier of CHD known to play a 
role in chamber formation and septation of the heart. A Tbx5 null allele was introduced to 
Ts65Dn mice, and newborn pups were sacrificed and examined for CHDs.  There is a 
significant difference between trisomic and euploid pups in the frequency of overriding 
aorta (OA).  About 58% of the trisomic Tbx5+/- mice present with OA and a ventricular 
septal defect (VSD), while only 18% of the euploid pups have this defect.  These results 
suggest that there is an interaction between Tbx5 and trisomy to increase the frequency of 
specific defects, and suggests a role for Tbx5 in development of the aorta.  Results also 
suggest that the Tbx5 protein is involved in the transcriptional regulation of trisomic 
genes.  
The possibility of using the Ts65Dn mouse model to study the role of the Sonic 
hedgehog (Shh) pathway in CHD is also discussed here. Shh is known to be involved in 
heart development; Shh null mouse embryos exhibit a variety of heart defects. Ts65Dn 
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mice showed a deficit in response to Shh in pharyngeal arches 1 and 2.  If this deficit 
extends to all trisomic cells then it could contribute to CHD in trisomy. Pharyngeal 
arches 4 and 6 contribute to heart development and a Shh deficit in those regions would 
certainly contribute to heart defects. Trisomy is a destabilizing factor that, along with 
other modifiers, can cause a significant insult to heart development. These studies help in 
understanding the influence of those factors on heart development. 
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Chapter 1: Introduction 
Down syndrome (DS), a result of having three copies of all or part of 
chromosome 21, is the most common live born autosomal aneuploidy.  It occurs in about 
1 in 700 live births [1].  The first clinical descriptions of DS were made by Jean-Étienne 
Dominique Esquirol and Édouard Séguin in 1838 and 1846, respectively. John Langdon 
Down provided a fuller clinical description in 1866 [2]. Dr. Jérôme Lejeune identified 
trisomy of human chromosome 21 (Hsa21) as the cause in 1959 [3]. In 1961 leading 
doctors and geneticists decided that the common term for the syndrome, “Mongolism,” 
was inappropriate and the name “Down Syndrome” was suggested in honor of Dr. Down.  
Most cases of trisomy 21 are due to the inheritance of an extra freely segregating Hsa21, 
but the syndrome can also be caused by a Robertsonian translocation between 
chromosome 21 and another chromosome in a parent of an individual with DS.  
Approximately 98% of cases result from errors in meiosis, and around 70% of those 
cases occur at meiosis I [4]. In prenatally diagnosed trisomy 21 fetuses 89% of the 
additional chromosomes were of maternal origin, and 11% were of paternal origin [5].   
DS is a complex developmental disorder with over 80 clinical features [6]; the 
most recognized being intellectual disability and craniofacial dysmorphology, occurring 
in all those diagnosed with DS.  It is the most common genetic cause of intellectual 
disability and a leading cause of congenital heart defects (CHDs) [7].  CHDs are the most 
common type of birth defect in live births [8], occurring in 1% of the population [9, 10].  
CHD is the most common cause of infant mortality due to birth defect and there are 
currently no ways to prevent it.  Furthermore, there is still much to be determined about 




The heart is the first functional organ in the embryo, indicating its importance to 
growth and survival.  Early in development, presumptive heart cells from the primitive 
streak migrate bilaterally towards the midline.  The bilateral heart fields unite to form the 
cardiac crescent (or cardiogenic mesoderm) [11]. This fusion creates a single tube at the 
midline. The posterior and anterior domains of the heart tube are established by a retinoic 
acid gradient, committing the posterior heart to becoming the atria [12]. The cardiac 
crescent consist of myocardium and endocardium, and its cells are known as the primary 
heart field (PHF). A second group of cells, known as the second heart field (SHF), are 
added to the crescent to help form and expand the tube [13-15].  The anterior-posterior 
polarity of the tube is converted to a left-right polarity with looping of the tube.   
After looping, endocardial cushions form from endothelial cells in the heart tube 
that undergo epithelial to mesenchymal transition (EMT) and migrate to regions filled 
with cardiac jelly. Two sets of these cushions form in the heart; one set partition the 
primitive atria and ventricles and the other set forms in the conotruncal region which will 
eventually give rise to the aorta and pulmonary artery.  The cushions will eventually fuse 
and develop into parts of the septa and valves of the mature heart. Defects in endocardial 
cushion formation, also known as atrioventricular septal defects (AVSD), are associated 
with DS [16].  
Heart looping brings about the formation of the different chambers of the heart, 
and brings the primitive chambers into the positions they will occupy in the final, mature 
heart.   The PHF contributes mostly to the atria and left ventricle of the heart, while the 
SHF contributes mostly to the outflow tract (OFT) and right ventricle. After heart 




of two separate septa, the septum primum and the septum secundum. Atrial septation 
begins with the formation of the septum primum, which grows from the roof of the 
posterior atrial wall.  The septum primum eventually fuses with the endocardial cushions, 
while apoptosis in the superior part of the septum primum creates an opening called the 
foramen secundum. Defects in the formation of the foramen secundum are the most 
common cause of ASDs [17-19]. The septum secundum then grows to fuse with the 
endocardial cushions, leaving an opening called the foramen ovale.  At or shortly after 
birth, pressure in the left atrium forces the septum primum against the foramen ovale, 
closing the opening and allowing for proper circulation.  
Septation of the OFT occurs at the same time as ventricular septation.  Prior to its 
septation the OFT begins to rotate, while the endocardium undergoes EMT and 
endocardial cushions form in the OFT. The cushions fuse and, along with the addition of 
cells that have migrated from the neural crest, separate the OFT. The OFT gives rise to 
the aorta, which connects to the left ventricle, and the pulmonary artery, which connects 
to the right ventricle. The ventricular septum is formed from two parts: the muscular and 
membranous portions. The muscular septum grows upwards towards the endocardial 
cushions, but stops growing before full septation is complete. Cells from both the left and 
right sides of the primitive ventricle form the septum but do not mix. The membranous 
portion is formed later, from the fusing of the encodardial cushions of the OFT. The 
septum is complete upon the joining of the endocardial cushions, atrial septum, muscular 
ventricular septum, and the dorsal mesenchymal protrusion (DMP). 
There are a variety of genes and molecular pathways involved in heart 




pathways such as signal transduction, chromatin regulation, transcription, and 
extracellular matrix production (reviewed in [20]). The Notch, Sonic hedgehog (Shh) and 
NFAT signaling pathways are important for the EMT process in the endocardial cushions 
of the heart. Defects in these signal transduction pathways can lead to defective 
development of the endocardial cushions and septation errors. Mutations in genes that 
encode for transcription factors can also lead to various heart defects.  The T-box and 
GATA families of transcription factors are important for heart development. Pitx2, 
another transcription factor, plays an important role in the left-right asymmetry of the 
heart. 
 Chromatin regulators and histone modifiers influence heart development as well.  
Mutations in the chromatin regulator Brg1, cause ventricular septal defects (VSDs) and 
problems in OFT development [21, 22]. Muations in histone deacetylases (HDACs) can 
also cause errors in development. Mouse knockouts of Hdac3 show VSDs and defects in 
the alignment of the aorta [23]. Even mutations in extracellular matrix (ECM) proteins 
can lead to heart defects.  Mutations in the ECM protein Fbln1 cause a variety of defects 
in the heart and affect septation and alignment of the OFT [24]. Mutations in the cell 
adhesion protein Ptk2 can cause defects affecting every structure in the heart (reviewed in 
[20]). Adding to its complexity, mutations in non-coding microRNAs have been found to 
lead to CHD as well.  Mutations in mir17, mir1a-2, and mir133a have all been associated 
with VSDs (reviewed in[20]). From the observation of the many pathways involved in 
heart development, it is clear that heart development is a highly complex process and one 





The Down Syndrome Heart Project (DSHP) aims to gather genetic information 
from those with DS and CHD  and to use that information to study the genetic origins of 
CHD.  Forty to fifty percent of individuals with DS have some type of CHD.  These are 
mostly septal defects of the heart, with AVSD being the most common.  Of those 
individuals with DS and a CHD, approximately 20% have an AVSD.  The frequency of 
AVSD in DS is about 2000 times higher than in the general population [25]. Since half of 
those with DS have a normal heart, additional genetic and environmental factors must 
interact with DS to cause CHD, i.e., trisomy 21 sensitizes the fetus to CHD, but is not 
sufficient to cause it. Thus, dosage effects of Hsa21 genes are a complex modifier that, in 
conjunction with other risk factors like single-gene variants, may increase susceptibility 
to CHD (Figure 1). Attempts to identify genes predisposing to CHD in DS have 
understandably focused on Hsa21, while there has been little consideration of disomic 
modifiers that contribute to this increased risk.  The DSHP uses the sensitized DS 
population to find disomic genetic modifiers of CHD that may contribute to CHD in all 
people, not just those with DS.  
Animal models are an important tool for understanding the pathogenesis of CHD 
and the molecular mechanisms that give rise to these conditions. Mice are small and 
easily housed and they exist as inbred strains, minimizing the effects of genetic 
variability. Heart development in the mouse is analogous to development in humans, 
making it a prime model system to study heart development. Conserved synteny between 






Figure 1. Threshold Hypothesis. Additive effects of individual modifier genes can reach a 
threshold whereby heart septal development is disrupted, but the likelihood of inheriting 
many predisposing modifiers is small (Eu with AVSD).  Trisomy 21 is a significant risk 
factor for CHD, but does not cause it (Trisomy 21). People with an extra copy of Hsa21 
may require fewer disomic or trisomic modifiers to reach the threshold (Ts 21 + 
modifiers). The relative contribution of the modifier in the sensitized Down syndrome 
population is therefore more readily detectable. Adapted with permission from Lippincott 
Williams and Wilkins/Wolters Kluwer Health: Li, H., et al. CIRCULATION: 





Hsa21 are found on mouse chromosome 16 (Mmu16), with smaller subsets on Mmu10 
and Mmu17 (Figure 2) [26]. Several mouse models have been generated to replicate the 
symptoms of DS in mice (Figure 3). The Ts1Cje, Ts1Rhr, and Ts65Dn mouse models are 
all partial trisomies of Mmu16, replicating various clinical features of DS [27-29].  The 
Tc1 mouse is a so-called “transchromosomic” line, carrying an almost complete copy of 
Hsa 21 [30]. In recent years two new mouse models of DS have been developed. The 
Dp(16)1Yey/+ mouse is trisomic for all regions of Mmu16 that are orthologous to Hsa21 
[31], and the Dp(16)1Yey/+, Dp(17)1Yey/+, Dp(10)1Yey/+ mouse is trisomic for all 
regions of the mouse genome orthologous to Hsa21 [32]. The most widely studied DS 
mouse model, Ts65Dn, is trisomic for a segment of Mmu16 containing about half of the 
mouse genes orthologous to Hsa21 [33]. These mice were the result of an induced 
chromosome breakage and translocation between Mmu17 and Mmu16. Ts65Dn mice 
display a number of the features of DS, but not all.  Ts65Dn mice have a similar 
craniofacial dysmorphology to that seen in DS [34], and also display a smaller 
cerebellum, analogous to what is seen in DS [35]. Ts65Dn mice do exhibit cardiac 
abnormalities, although these occur at a lower frequency than in humans [36, 37]. Four 
percent of Ts65Dn mice have a septal defect, while 18% have OFT defects [36].  
The goal of this thesis was to expand knowledge of the genetic pathways involved in the 
origin of CHD. Using the Ts65Dn mouse model we set out to examine a disomic 
modifier of CHD, the Tbx5 gene, and investigate the genetic origin of CHD.  Trisomic 
populations are sensitized to CHD, making them prime candidates for this investigation. 
A multitude of genes affecting diverse pathways affect heart development, indicating that 




aimed to delve into those interactions by focusing on a known modifier of heart 





























Figure 2. Hsa21 orthologs on Mmu10, 16, and 17. Hsa21 is syntenic with regions on 
Mmu 17, Mmu 16, and Mmu 10. The largest region of synteny is on Mmu16. Reprinted 
by permission from Macmillan Publishers Ltd: Antonarakis,S.E. et al. NATURE 













Figure 3. Mouse models of DS. Hsa21 (in blue) and the syntenic mouse chromosomes 
(Mmu 16, orange, Mmu 17, purple, Mmu10, green). The trisomic regions of several of 
the well-established mouse models of DS are aligned to the corresponding parts of the 
human and mouse genome. Adapted from Sheppard, O. et al. Mouse models of 
aneuploidy. The Scientific World Journal. 2012; 2012:214078. Reprinted with permission 









Chapter 2: Tbx5 and trisomy interact to alter the incidence of specific heart defects 
 
Introduction 
We consider a known contributor to heart development, Tbx5, and its role as a 
disomic modifier of septal defects in Ts65Dn mice. Tbx5 is a member of the T-box 
family of transcription factors.  The defining family feature is a conserved sequence in a 
DNA binding domain that extends across a region of 180-200 amino acid residues called 
the T domain [38, 39]. All members of the family are known to be involved in regulation 
of transcriptional activity, some as activators and others as repressors. Tbx5 activation of 
transcription has well-described effects in cardiac and limb development [40, 41]. 
Mutations in the gene are associated with Holt-Oram syndrome; patients diagnosed with 
the syndrome present with various heart defects and skeletal abnormalities in the hands 
and arms. About 85% of affected individuals have a structural heart defect and/or 
abnormalities in the cardiac conduction system. Holt-Oram patients most often present 
with ASDs and VSDs. 
Several different roles for the gene in cardiogenesis have been found. Tbx5 has 
been found to play a role in activating transcription of various target genes including Gja, 
and Anf [42].  In order to carry out its transcriptional activity the protein has been found 
to interact with various other transcription factors including Sal4 [43], Mef2c [44], 
myocardin [45], and members of the GATA family [46, 47].   Tbx5 is important for 
cardiomyocyte differentiation [48, 49], cell proliferation [50, 51], and cardiac conduction 
[52]. Transcription of the gene is also required for reprogramming differentiated somatic 
cells into functional cardiomyocyte-like cells [53]. The majority of work regarding Tbx5 




expressed in the left ventricle (LV) and both atria during chamber maturation and 
septation [54]. The ventricular septum forms at the boundary between Tbx5-expressing 
LV and non Tbx5-expressing RV [54, 55]. Ectopic expression in the right ventricle or 
deletion of Tbx5 in the left ventricle of mice suppresses formation of the ventricular 
septum, resulting in formation of a single ventricle [56]. Conditional knockouts of the 
gene in the SHF cause ASDs to form in mice [57]. Its importance in septation of the heart 
suggests that variants affecting Tbx5 expression might affect septation in a trisomic (Ts) 
mouse model of DS. We examined the role of Tbx5 in septal development by crossing 
Ts65Dn mice with mice heterozygous for a null allele for Tbx5. 
We used a mouse model with a null allele for Tbx5 to study the effects of this 
gene on septal development in conjunction with trisomy [42]. Homozygous null Tbx5-/- 
embryos (Black Swiss/SvJ background) die by embryonic day 10.5 (E10.5) and lack 
cardiac looping and endocardial cushion formation, among other severe defects [42]. 
Heterozygote mice on that same genetic background exhibit ASDs and VSDs. The 
viability of and defects observed in Tbx5+/- mice is greatly influenced by genetic 
background. Deviation from the expected Mendelian frequency varies with the genetic 
background of the mice, indicating that prenatal loss has occurred and that difference in 
genetic background plays a role in phenotype. Thus, the effects of Tbx5 dosage are 
susceptible to additional genetic modifiers.  
The interaction between Tbx5 dosage and trisomy showed a dramatic increase in 
defects affecting aortic alignment and an effect on left-right patterning of the heart. The 
Pitx2 gene is an important determinant of left-right asymmetry of the heart. It confers left 




60].  Other transcription factors in the T-box family are known to regulate Pitx2 
expression [61], and Pitx2 regulates Tbx5 expression in the abdominal wall during 
development [62]. Pitx2 expression in Trisomic (Ts), Tbx5+/- embryos was examined to 
look for altered atrial identity in these mice. The molecular mechanisms by which Tbx5 
influences heart development are incompletely described and its possible interactions 
with genes on Hsa21 are unknown. Here we provide evidence of an interaction between 
Tbx5 and trisomy, and the effects of that interaction on trisomic gene expression and left-
right patterning of the heart. 
Methods 
Animal Husbandry 
Animals were maintained in a virus and antibody-free facility with food and water 
ad libitum. Ts65Dn mice (B6EiC3H-a/A-Ts(1716)65Dn)  were obtained from The 
Jackson Laboratory and maintained on the B6;C3H background. Tbx5 heterozygous null 
mice (Tbx5+/-) were obtained from Dr. Jonathan Seidman [42]. We backcrossed the 
Tbx5+/- mice onto a C57BL/6J background. Mice used in this study were the progeny of 
female Ts65Dn mice. All procedures were approved by the Institutional Animal Care and 
Use Committee. 
Genotyping 
Genomic DNA was extracted from tail tips of mice by heating at 90⁰C for 2 hours 
in 10mM NaOH, 0.2mM EDTA, and used for genotyping by PCR. Sequences of primers 
for Ts65Dn genotyping are as follows: C17F: 5’-GTGGCAAGAGACTCAAATTCAAC-





3’. For Ts65Dn genotyping, PCR was done under the following cycling conditions: 95̊ C 
3 min, (94 ˚C 10s, 58.7˚C 20s, 72˚C 27s) for 31 cycles, 72 ˚C 5 min. In the cuploid mice 
a region of 600 base pairs (bp) was amplified. This band in addition to 275 bp band was 
seen in trisomic mice. For Tbx5 genotyping, three primers designed to amplify either the 
wild type or null alleles were added together in each reaction [42]. The sequences of the 
primers for Tbx5 genotyping are as follows: 3F2: 5’-CCCAGCGGCAGGCGTAGAC -3’; 
Loxp-F: 5’-GCAGCGCAGTCCTCACCAG -3’;   Loxp-R: 5’-
AAATTCCAACCCCTTCCACAGAT -3’. The PCR was done under the following 
cycling conditions: 94˚C 3 min, (94 ˚C 30s, 59.7˚C 30s, 72˚C 1 min) for 35 cycles, 72 ˚C 
10 min. The region amplified in the mutant allele was 480 bp, and the region amplified in 
the wild type allele was 158 bp. 
Histology 
All progeny of Ts65Dn x Tbx5+/- crosses were collected at postnatal day 0 (P0) 
within hours of birth. The pups were euthanized and thoraxes were removed and fixed in 
10% formalin for at least 48 hours. The tissue was dehydrated in 30%, 50%, and 70% 
ethanol for 1 hour each before being stored at 4⁰C until embedded in paraffin. The 
paraffin blocks were sectioned at 7μm by standard methods, and stained with 
hematoxylin/eosin using standard methods. The heart morphology in each animal was 
scored under a dissecting stereomicroscope (Nikon SMZ1500, Japan) by at least two 
individuals blinded to genotype. Dr. Ivan Moskowitz also verified all CHDs. Pictures 




In Situ Hybridization 
E13.5 embryos were fixed in 4% paraformaldehyde for 1 hour, rinsed in 1X PBS 
three times for 5 minutes, and then dehydrated in 25%, 50%, and 70% ethanol for 1 hour 
each.   After dehydration the embryos were stored at -20⁰C in 70% ethanol until 
embedded in paraffin and sectioned according to standard methods. We performed in situ 
hybridization using traditional dioxigenin (DIG)-labeled RNA probes detected with 
alkaline phosphatase (AP)-conjugated anti-dioxigenin antibody using nitro blue 
tetrazolium chloride / 5-bromo-4-chloro-3-indolyl-phosphate toluidine-salt (NBT/BCIP) 
substrate. DIG RNA labeling mix, anti-DIG-AP antibody, blocking reagent, NBT/BCIP 
were all purchased from Roche Applied Science (Indianapolis, IN) and used according to 
the manufacturer's instructions with minimal modifications. The Pitx2 antisense and 
sense probes were described earlier [63]. Images were taken with the Leica DMRB 
upright light microscope using the Leica Application Suite Software v4.3 (Leica 
Microsystems-W. Nuhsbaum Inc., McHenry, IL). Composite images were compiled 
using Adobe Illustrator CS4 (Adobe Systems, San Jose, CA). 
Statistical Analysis 
A chi-squared test was used to determine if the occurrence of genotypes resulting 
from a Ts65Dn x Tbx5+/- mating fit Mendelian ratios. The incidence of various heart 
defects for different genotypes was compared by Fisher’s test using GraphPad Prism 
version 5. A 2x2 contingency table was constructed for each defect, comparing animals 
that had that particular defect and animals that did not. A p-value where p<0.05 was 





Viability of Tbx5+/- mice is dependent on genetic background 
B6.Tbx5+/− male mice were crossed to Ts65Dn females to examine the role of Tbx5 as a 
modifier of CHD. Genetic background of the Tbx5 mice affected viability (Table 1). At 
birth, Tbx5 genotypes appeared at Mendelian ratios (χ2=1.42, df=1, p=0.23) on a B6 x 
C3H (75% B6, 25% C3H) background (Table 2), but by weaning, the frequency of the 
Tbx5+/- genotype was 21% rather than the expected 50%. On an inbred B6 background, 
the frequency of the Tbx5+/- genotype is 9% at weaning. Thus, it appears that genetic 
factors contribute to embryonic and perinatal lethality associated with Tbx5+/-. 
Trisomy affects patterns of CHD in Tbx5+/- mice  
Progeny of the Ts65Dn x Tbx5+/- crosses were collected within hours of birth, prepared 
for histology, and assessed for the presence of CHD. All animals examined for CHD 
were on the B6 x C3H (75% B6, 25%C3H) background. There is some loss of Ts65Dn 
fetuses during late gestation, and the observed frequency of 42% trisomic pups at P0 
(Table 2) was in the expected range [64]. CHD is highly penetrant in Tbx5+/- mice and we 
saw only a slight overall increase in the percentage of heart defects when the null allele 
occurred on a trisomic background (Table 3). However, the pattern of effects was altered 
significantly by trisomy.  
We observed overriding aorta (OA) in ~58% of Ts, Tbx5+/- mice but only ~18% of 
euploid (Eu), Tbx5+/-, a significant difference (Table 3, p=0.0004).  OA consists of a VSD 
and an improperly positioned aorta directly over the VSD (Figure 4). A difference in 




    








aBruneau, B.G., et al., A murine model of Holt-Oram syndrome defines roles of the T-box transcription 




Frequency of Tbx5+/- 
genotype at weaning 
C57BL/6J 9% (n= 528) 
B6;C3H (75% B6, 25% C3H) 21% (n=131) 
129SvEv/129SvJ 10%a 




Table 2. Ratios of all genotypes in a Ts65Dn x Tbx5+/- cross on a B6;C3H (75% B6, 25% 
C3H) background (at birth). 
Genotype 
 Number (%), n=180 
Tbx5+/+ 
 52 (28.9%) 
Tbx5+/- 
 51 (28.3%) 
Ts65Dn 
 46 (25.6%) 
Ts65Dn, Tbx5+/- 





Table 3. Congenital heart defects in P0 trisomic and euploid Tbx5+/- mice 
a Several animals had more than one defect. 
b There is a significant difference between euploid and trisomic Tbx5 heterozygous mice in the occurrence 
of overriding aorta (p=0.0004). 
cThe difference between euploid and trisomic Tbx5 heterozygous mice in AVSD is not significant but a 
larger sample size may have shown significance. (p=0.07) 
  
Genotype ASD VSD 
only 
Overriding 













7    
(17.5%) 
4      
(10%) 































Figure 4. CHDs seen in P0 trisomic and euploid Tbx5+/- mice. Coronal histological 
sections of wild type (A) and Ts, Tbx5+/- (B-D) newborn mice stained with H&E. 









Ts, Tbx5+/- littermates exhibiting the defect (p=0.07), were also observed. ASDs, VSDs 
and Gerbode’s defect, an abnormal communication between the right atrium and left 
ventricle, were also seen (Figure 4) but none reached statistical significance.  Numira 
Biosciences performed Virtual Histology™ on six Ts Tbx5+/- mice.  Three of these 
animals were affected, with an AVSD, ASD, and VSD, respectively.  
Atrial isomerism in trisomic Tbx5 heterozygotes 
OA and Gerbode’s defect are seen more often in trisomic Tbx5+/- mice than in their 
Tbx5+/- littermates.  We hypothesized that these defects might be accompanied by atrial 
isomerism. In this situation both atria are mirror images of one another and lack the 
typical morphological and molecular characteristics of the right or left atrium.  Pitx2 is 
specifically expressed in the left atrium, and its expression is absent or ectopically 
expressed in the right atrium in cases of atrial isomerism [58]. To determine whether 
atrial isomerism occurred in trisomic mice, in situ hybridization for Pitx2 was performed 
on coronal paraffin sections of E13.5 torsos.  Pitx2 expression can be seen in the left 
atrium of the heart in euploid embryos, but that expression is much weaker in the mutants 
(Figure 5).  The weak Pitx2 expression in the atria of Ts, Tbx5+/- embryos suggests that 
these embryos have defects in laterality (i.e., atrial isomerism). Atrial isomerism likely 
contributes to the dramatic increase in OA in the trisomic, Tbx5+/- animals. Note that 
Pitx2 expression in other organs was comparable between the two genotypes (Figure 6). 
Discussion 
Heart development is a complex process. The role of genetic modifiers is clear 





Figure 5. Pitx2 expression in E13.5 hearts to determine atrial isomerism. In situ 
hybridization of coronal sections of wild type (A,B) and Ts, Tbx5+/- (C,D) E13.5 
embryonic hearts. Pitx2 expression can be seen in the left atrium of the WT animals (A). 
Pitx2 expression is much weaker and confined to a smaller area (arrowheads) in the 






Figure 6. Pitx2 expression in various organs in E13.5 wild type and trisomic, Tbx5+/- 
mutant embryos.  Note that Pitx2 expression in the trisomic, Tbx5+/- animals is 
comparable to that seen in wild type embryos in the pituitary, tooth bud, midbrain, and 





models. Modifiers also affect Tbx5, which is seen when the Tbx5 null allele is bred onto 
different genetic backgrounds. Holt-Oram patients who inherit the same mutation in 
TBX5 have variable phenotypes, indicating that additional factors affect development 
[65].  Incomplete penetrance of CHD in DS indicates that other interactions between 
trisomy and other factors can alter developmental outcomes. Previous work from our lab 
and others has shown effects of the interactions between trisomy and disomic modifier 
genes, both in both humans and mouse models [25, 37]. Our data support findings in 
people showing that DS and TBX5 mutations can cause multiple, severe defects when 
combined [66].  Individuals with DS and mutations in TBX5 displayed OA and a number 
of additional defects.  
Previous studies on Tbx5 and its role in heart development have emphasized its 
importance to septation of the heart.  Because of this we expected to see a difference in 
susceptibility to septal defects in the trisomic, Tbx5+/- mice. Our results showed no formal 
statistical significance between the euploid and trisomic mice when looking at ASDs, 
VSDs, or AVSDs.  However, there was a trend towards more AVSD (p=0.07) in the 
trisomic Tbx5+/- mice. While the occurrence of AVSD was not statistically significant, it 
is possible that a larger sample size may yield significant results. AVSDs are extremely 
severe and may lead to death in utero.  It is possible that the trisomic mice show 
significantly more of these defects, but the mice die prenatally.  To answer this question, 
a future direction would be to repeat this study and look for these defects before birth. 
Our data have also demonstrated a role for the Tbx5 gene beyond cardiac 
septation. The appearance of OA, a phenotype affecting OFT development, suggests roles 




the OFT in mice, but expression of the gene has been found in the OFT of chick embryos 
during development [67]. Haploinsufficiency of Tbx5 has been found to hinder 
cardiomyocyte development, which is known to cause alignment defects of the aorta. 
Combined, these data suggest that there is a potential role for Tbx5 in the development of 
the aorta. 
These results show a clear interaction between trisomy and Tbx5 dosage.  A 
combination of the two factors correlated with changes in the expression of the Pitx2 
gene. Pitx2 regulates left atrial identity, and its expression is critical for development of 
left-right asymmetry in the heart and gut [58, 59, 68-71]. Defects in atrial identity, or 
atrial isomerism, occur in mice with reduced Pitx2 expression [59]. In Pitx2 mouse 
mutants the OFT is shifted dorsally towards the right, a condition that contributes to OA 
[72]. In fact, OA is thought to be a less severe form of a defect called double outlet right 
ventricle (DORV), in which the aorta arises mostly from the right ventricle instead of the 
left.  Pitx2 mouse mutants frequently exhibit this defect [60, 69, 71, 73]. Based on these 
previous reports and our findings that Pitx2 expression is reduced in the atria of E13.5 Ts, 
Tbx5+/- embryos, it is likely that atrial identity is altered in these mice, leading to an 
increase in OA. We have provided evidence suggesting that left-right asymmetry is 
adversely affected in Ts, Tbx5+/- mice. 
We have shown that multiple pathways are affected when trisomy and Tbx5 
haploinsuffiency are combined. The outcome of development can be altered when 
mutations in a disomic modifier of CHD is combined with trisomy. Alterations in Pitx2 
expression are known to lead to deficits in the left-right pathway and the development of 




expression, likely causing defects in the left-right asymmetry of the heart in these mice. 
Our findings document previously unknown connections between Tbx5 and trisomic 
genes and their influence on the appearance of structural heart defects and left-right 





Table 4. Euploid and trisomic P0 animals with multiple defects 
 
  




13 (32.5%) 13 (32.5%) 14 (35%) 40 
Ts65Dn 
Tbx5+/- 




Chapter 3: Trisomic gene interaction with Tbx5 
Introduction 
 Previous studies in our lab have found interactions between trisomy and disomic 
genes, Hey2 and Creld1.  Hey2 is a member of the hairy and enhancer of split-related 
(HESR) family of transcription factors.  These factors interact with histone deacetylase 
complexes to repress transcription.  Mutations in the gene have been identified in DS 
patients with CHD but not in euploid individuals with CHD [74, 75]. Homozygous Hey2 
knockout mice die in early embryogenesis and always present with a septal defect [76, 
77].  Hey2 is a disomic modifier of CHD on a trisomic background. Hey2+/- mice 
presented with no septal defects but the incidence increased to 24% when Hey2+/- mice 
were put on a triomic background [37]. 
Creld1 encodes a member of a family of epidermal growth factor related proteins. 
It was originally identified as a candidate for the AVSD2 locus [78].  The gene is 
associated with AVSD [16, 79] and mutations in it have been found in people with DS 
and CHD [37, 80]. Creld1+/- mice did not show any septal defects but the incidence of 
septal defects increased to 33.3% when the mice were crossed on to a trisomic 
background [37].  To identify the trisomic gene with which Creld1 might be interacting, 
Creld1+/- mice were crossed with the Ts1Rhr and Ts1Cje mouse models of DS.  The 
frequency of septal defects on the Ts1Rhr and Ts1Cje models was unchanged when the 
Creld1 haploinsufficiency was added (H. Li, unpublished data).  This indicated that a 
gene trisomic in the Ts65Dn model but not the others was a candidate for that interaction.  
The Jam2 gene was chosen as a candidate due to its expression in heart and its 




mouse model of DS [81]. The histology data presented in chapter 2 indicate an 
interaction between a disomic gene (Tbx5) and trisomy. Here, the Ts65Dn mouse model 
was used to identify trisomic genes that interact with Tbx5.  
The molecular mechanisms by which Tbx5 influences heart development are 
incompletely described and its possible interactions with genes on Hsa21 are unknown. 
The increased incidence of OA in Ts, Tbx5+/- mice may be caused by an interaction 
between Tbx5 and a trisomic gene(s) that is regulated by this transcription factor. Tbx5 
target genes have been identified via high throughput methods but few have been verified 
[82]. The few verified transcriptional targets of Tbx5 include Fgf10 [83, 84], Gja5 [42], 
and Anf [42, 49]. Tbx5 has also been implicated in the transcriptional regulation of Gata4 
[42, 85] and Hey2 [42], but these targets have yet to be verified. We sought to add to the 
list of Tbx5 transcriptional targets by identifying trisomic genes that may be regulated by 
Tbx5. Trisomic genes with T-box binding elements (TBEs), a known role in heart 
development, and an association with the Tbx5 protein were identified, and their 
transcript levels in trisomic and euploid Tbx5+/- mice were examined. 
Methods 
Identification of candidate genes 
One hundred nine (109) genes that are trisomic in Ts65Dn mice were examined 
for localization of expression in the heart using the following databases: EMAGE gene 
expression database (http://www.emouseatlas.org/emage/home.php), VisiGene image 
browser (http://genome.ucsc.edu/cgi-bin/hgVisiGene?hgp_listSpec=), the Chromosome 




database (http://www.informatics.jax.org/expression.shtml). The 64 trisomic genes 
expressed in heart during development, according to the above databases, were compared 
to a list of genes bound by Tbx5 in a ChIP study [86]. A list of 43 trisomic candidate 
genes that were expressed in heart and bound by Tbx5 was then generated (Figure 7, 
Table 5).  From the list of 43 genes, 6 were chosen as top candidates. The top 6 genes 
were the only genes out of the 43 which had TBEs in their promoter regions, were found 
to be bound by other heart specific transcription factors, had high evolutionary 
conservation in the TBE containing regions, and were previously implicated in heart 
development. The Transcription Element Search System (http://www.cbil.upenn.edu/cgi-
bin/tess/tess) [87] was used to search for the TBEs (RGGTGTVR)  [88]. 
Real-Time Analysis of Gene Expression  
Total RNA was extracted from the hearts of E11.5 embryos using the RNeasy 
mini kit (Qiagen). Heart tissue from 3-6 embryos of each genotype was pooled together. 
cDNA synthesis was carried out with the First-Strand cDNA synthesis kit (Life Sciences) 
using 1 µg of total RNA as template. PCR was carried out on a 7500 Real-Time PCR 
System (Applied Biosystems) using POWER SybrGreen master mix (Applied 
Biosystems). 50 ng of cDNA was used in each PCR reaction. Each PCR run consisted of 
three technical replicates, and at least three biological replicates were performed. Primers 









Figure 7. Identifying trisomic gene candidates for Tbx5 interaction. Gene expression 
database were searched to find expression domains of all Ts65Dn trisomic genes. Genes 
that were expressed in the heart during development were further investigated for 
interaction with Tbx5 using data from a ChIP study.  Of the 43 genes associated with 
Tbx5 in the ChIP study 6 were chosen as candidate based on the appearance of a T-box 






Table 5. Forty-three Ts65Dn trisomic genes expressed in heart during development and 
bound by Tbx5 in a ChIP experiment 















































a He, A., et al., Co-occupancy by multiple cardiac transcription factors identifies transcriptional enhancers 





Rcan1-F: 5’-TTGTGTGGCAAACGATGATGT-3’; Rcan1-R: 5’-
CCCAGGAACTCGGTCTTGT-3’; Gapdh-F: 5’-TGCACCACCAACTGCTTAG-3’; 
Gapdh-R: 5’-GATGCAGGGATGATGTTC-3’. The PCR was done under the following 
cycling conditions: 95˚C 15 min, (95 ˚C 15s, 60˚C 1 min) for 40 cycles, 95 ˚C 15 sec, 
60⁰C 1 min, 95 ˚C 15 sec. Expression of candidate genes was normalized to Gapdh.   
Creation of Tbx5 constitutively over-expressing cells 
A Tbx5 cDNA clone was obtained from the I.M.A.G.E. consortium and subcloned 
into the pcDNA3.1+ vector (Life Technologies), putting it under the control of the CMV 
promoter. NIH-3T3 cells were transfected with the pcDNA-Tbx5 construct using 
Lipofectamine 2000 (Life Technologies). Stably transfected cell lines were selected with 
1 mg/ml Geneticin (Gibco). The cells were maintained in Dulbecco’s Modified Eagle 
Medium with high glucose (Life Technologies), 10% fetal bovine serum, 1 mg/ml 
Geneticin, 1X glutamine and penicillin/streptomycin at 37⁰C and 5% CO2. 
Luciferase Assay 
The promoter region of Adamts1 that was bound by Tbx5 in a ChIP study [86] 
was amplified by PCR with the insertion of cut sites for KpnI and XhoI. PCR primers are 
as follows, F: 5’-GGCGCTTATGGTACCTGGTCACACTTTTTTTGG-3’; R: 5’- 
GGCGCTTATCTCGAGCACCTTCACAGAGGCTCA-3’.  The amplified region was 
subcloned into the pGL3 basic vector (Promega). Tbx5 siRNA and scrambled siRNA 
were purchased from Life Technologies. The constructs and siRNA were transfected into 
NIH-3T3 cells constitutively over expressing Tbx5 using Lipofectamine 2000 (Life 




scintillation and luminescence counter (Perkin-Elmer) using the Dual Luciferase Assay 
Kit (Promega). 
Statistical Analysis 
The relative quantification of gene expression and the luciferase assays comparing 
different constructs were compared by Student’s t-test. At least three biological replicates 
for the quantification of gene expression were compared, with each biological replicate 
consisting of three technical replicates. All tests were 2-tailed, and P<0.05 were 
considered significant.  
Results 
Candidate trisomic genes interaction with Tbx5 
The simplest explanation for the increased incidence of specific defects in Ts, Tbx5+/- 
mice is an interaction between Tbx5 and a trisomic gene(s) that is regulated by this 
transcription factor. We considered the 109 genes that are trisomic in Ts65Dn mice and 
generated a list of potential candidate genes based on expression patterns (Figure 7). 
Sixty-four of these genes are expressed in the heart during development. Of those 64 
genes, 43 contained regions that associated with Tbx5 in a ChIP study [86]. However, 
examination of these 43 revealed a T-box consensus binding site in only six. Based on 
prior reports of possible effects on heart development, evolutionary conservation, the 
presence of T-box binding sites, and binding sites for other heart specific transcription 
factors, we selected three of the six, Dyrk1a, Rcan1, and Adamts1, for further 




three [86]. Using TESS, predicted T-box binding sites were found in the first exons 
and/or promoter regions of those genes [87]. 
Trisomy and Tbx5 haploinsufficiency affect expression of genes in the NFAT 
pathway 
 Quantitative PCR was used to determine transcript levels of trisomic genes that are 
regulated by Tbx5, in hearts of trisomic and euploid, Tbx5+/- embryos at E11.5. We also 
examined expression of the non-trisomic Nfatc1 gene because its activity is regulated by 
two of our candidate trisomic genes (Figure 8) [89, 90], and its expression is altered when 
Tbx5 is over expressed [82]. Levels of Nfatc1 were increased in Eu, Tbx5+/- mice 
compared to wild type controls (p=0.003) (Figure 9). In contrast, expression of Nfatc1 in 
Ts, Tbx5+/- mice was reduced (p=0.01). Dyrk1a was up regulated in both Ts65Dn 
(p=0.02), and Tbx5+/- mice (p=0.01) (Figure 9), reflecting separate influences of both 
trisomy and Tbx5 dosage on expression of Dyrk1a. Surprisingly, expression levels of 
Dyrk1a in Ts, Tbx5+/- mice were half of the wild type level (p=0.002) (Figure 9). Only the 
increase in Rcan1 levels in Tbx5+/- mice compared to euploid animals was statistically 
significant (p=0.01) (Figure 9).  
The data suggests that Tbx5 represses genes in the NFAT pathway.  Although 
trisomy alone does not affect the pathway, when the two factors are present together, 
transcription of NFAT pathway genes is repressed. The interaction of Tbx5 and trisomy 
has an effect on gene transcription that is not seen in trisomy alone or Tbx5 
haploinsufficiency alone. Tbx5 haploinsufficiency, either directly or indirectly, alters 








Figure 8. Role of trisomic genes Rcan1 (Dscr1) and Dyrk1a in regulation of the 
translocation of Nfatc1 protein within the cell. Entry of calcium into the cell leads to the 
activation of calcineurin (Cn) and the de-phosphorylation of Nfatc family members. 
Rcan1 binds Cn to inhibit its de-phosphorylation of Nfatc1 and prevents Nfatc nuclear 
entry. De-phosphorylation of Nfatc1 by Cn allows the protein to move into the nucleus. 
Once in the nucleus Nfatc1 induces transcription of several genes including Nfatc1, 
Dyrk1a, and Rcan1. Dyrk1a aids in phosphorylating Nfatc1, promoting its movement out 
of the nucleus. Others have proposed that an increase in Rcan1 and Dyrk1a, which is 
what is expected to occur in trisomy 21, will cause a slower entry and a quicker exit of 
Nfatc family members from the nucleus [90]. Reprinted by permission from Macmillan 













Figure 9. Quantitative PCR of candidate genes in E11.5 hearts.  Quantitative PCR of 
candidate gene expression levels in 3-6 pooled E11.5 embryonic hearts. Expression levels 
of Nfatc1 (A), Dyrk1a (B), Rcan1 (C), and Adamts1 (D). Levels of Nfatc1 are 
significantly decreased in Ts, Tbx5+/- mice (0.2x, p= 0.01) and increased in euploid 
Tbx5+/- mice (2.3x, p= 0.003). Transcript levels of Dyrk1a are significantly increased in 
Tbx5+/- (4.6x, p= 0.01) and Ts65Dn mice (2.4x, p= 0.02).  In the trisomic Tbx5+/- mice, 
Dyrk1a is decreased by half compared to WT mice (p= 0.002). For Rcan1 the only 
significant difference is between the WT and euploid Tbx5+/- mice. Rcan1 expression is 
up regulated 1.7x in the Tbx5+/- mice (p=0.01). For the Adamts1 assay levels are 
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heart. Our data suggests that the NFAT pathway is affected during development of Ts, 
Tbx5+/- mice. 
Tbx5 dosage and binding alters transcription of Adamts1         
Adamts1 transcript levels were significantly increased in Eu, Tbx5+/- mice (p=0.02) 
(Figure 9), suggesting that Tbx5 acts as a repressor of Adamts1. Changes in gene 
expression for the other genotypes did not reach statistical significance. We tested a 
putative Tbx5 binding site identified in the Adamts1 locus [86] using a luciferase reporter 
assay. A 238 bp region located 121 bp upstream of the Adamts1 transcription start site 
was amplified by PCR and cloned into the pGL3 luciferase vector (Figure 10). This 
construct was transiently transfected into cells stably over expressing Tbx5 and luciferase 
levels were measured. We found a significant increase in luciferase levels when 
comparing the pGL3 transfected cells with those transfected with the Adamts1 -121 
construct (p=0.00014) (Figure 11). Introduction of siRNA directed at Tbx5 reduced this 
effect (p=0.006). Thus while the overall effect of Tbx5 is repressive, binding of Tbx5 at 
the Adamts1 -121 region alone positively regulates transcription. 
Discussion 
We observed effects of both Tbx5 and trisomy on the NFAT signaling pathway, 
which is important for proper development of the cardiac septa, valves, and OFT [91-93]. 
Dyrk1a and Rcan1 are trisomic inhibitors of NFAT signaling [89, 90, 94] (Figure 8), and 
their over expression down regulated Nfatc1 protein expression in E13.5 mouse embryos 
[90].  Our q-PCR data show trisomy or reduction in Tbx5 both resulted in increased 








Figure 10. Region of Adamts1 gene inserted into pGL3 vector.  The region highlighted in gray contains the consensus T-box binding 
site (RGGTGTVR) and was amplified by PCR and cloned into a pGL3 luciferase vector (Promega). This region was associated with 










Figure 11. Effects of Tbx5 over expression on transcription of an Adamts1 luciferase 
construct. All constructs showed significantly higher luciferase expression when 
compared to the pGL3 luciferase construct backbone. Cells transfected with the Adamts1 
-121 construct and a Tbx5 siRNA showed significantly lower luciferase levels when 
compared to those transfected with the -121 construct alone (p=0.007), compared to 
ADAMTS1 -121). Graph represents one experiment representative of all replicates. The 
region inserted into the basic pGL3 vector is 121 bp upstream of the Adamts1 gene and 
associated with Tbx5 in a ChIP study. Tbx5 over expressing cells were harvested 48 
hours after transfection. The FGF10-luciferase construct was used as a positive control. 
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complex in the presence of trisomy; reduced expression was seen when the Tbx5 null 
allele occurred in trisomic mice.  There are two likely reasons why our results differ from 
the previous study.  In the previous studies [90] only Dyrk1a and Rcan1 were up 
regulated, causing down regulation of the Nfatc1 protein, but many more genes were up 
regulated in our trisomic mice and our study examined transcript levels not protein. It is 
clear that alterations in NFAT signaling correlate with the combination of trisomy and 
Tbx5 haploinsufficency.  This is evidence that Tbx5 dosage can have a significant effect 
on the NFAT pathway on the background of trisomy.  
 Questions that arise when considering these data are, “What specific effect is the 
combination of Tbx5 haploinsufficiency and trisomy having?,” and “What mediates that 
effect?” Trisomic mice have three copies of Rcan1 so transcriptional activation of this 
gene would result in negative regulation (i.e., repression) of NFAT signaling. Since 
NFAT signaling regulates EMT in the endocardial cushions it is likely that modulation of 
the NFAT pathway by either trisomy or Tbx5 dosage could result in an error during 
development of the cardiac cushions.   Indeed, loss of tbx5 in zebrafish leads to an 
increase in valve tissue, while knockouts of Nfatc1 in mice show stunted or absent valves, 
as well as VSDs, suggesting that the increase in Nfatc1 due to knockdown of Tbx5 could 
play a role in the defects seen in the mice described here [92, 93, 95]. Interestingly, 
cardiac defects in zebrafish with mutations in tbx5 are rescued by addition of cytosolic 
CAMK-II [96], which inhibits the NFAT pathway by interacting with calcineurin.  In rat 
ventricular myocytes, expression of a constitutively active CAMK-II protein inhibited 
nuclear translocation of Nfatc3 [97]. Reduction in dosage of Tbx5 could lower CAMK-II 




may regulate expression of CAMK-II which in turn negatively regulates NFAT signaling.  
This model would explain the increase in expression of Nfatc1 in mice heterozygous for 
the Tbx5 null allele.   An investigation into CAMK-II levels and Nfatc1 protein 
localization in these mice would be essential to investigate this hypothesis further. 
Our data also show that Tbx5 dosage affects the expression of the Adamts1 gene. 
Adamts1 is important in the development of the extracellular matrix in the endocardial 
cushions, and is a regulator of the VEGF pathway.  Reports show that Adamts1 blocks 
proliferation initiated by the VEGF pathway and also blocks Vegf from binding to its 
receptor [98]. An excess of variants in VEGF pathway genes is associated with DS-
related AVSD [25]. Binding of Tbx5 to the Adamts1 promoter induces expression in 
luciferase assays while haploinsufficiency of Tbx5 alters expression of Adamts1 in E11.5 
hearts, showing that Tbx5 has a role in the regulation of Adamts1 transcription. When 
Tbx5 siRNA was added expression was down regulated; although, the addition of Tbx5 
siRNA did not return the luciferase levels to that of the control. These results indicate that 
there may be another factor that co-regulates Adamts1 expression along with Tbx5.  
Expression of Adamts1 is repressed by Brg1, a protein that complexes with Tbx5 [99], 
and binds the promoter region of the Adamts1 gene [100]. Studies of Brg1+/-;Tbx5+/- mice 
found evidence that the two proteins interact in vivo, and that reduced dosage of Tbx5 
results in reduced occupancy of Brg1 at known Tbx5 target genes [22]. The authors 
suggest a model based on allelic balance between Tbx5 and Brg1 that would explain the 
results seen here. When the two alleles are unbalanced each has the opportunity to bind 
with other factors, including hypothetical repressors and activators. In accordance with 




potentially altering gene transcription, and increased dosage of Tbx5 would allow Tbx5 to 
interact with other factors, again altering gene transcription. 
 Our quantitative PCR results suggest that Tbx5 may act as a repressor of 
Adamts1 expression in vivo (Figure 8). The contradiction in the results of our quantitative 
PCR and luciferase assays can be explained by the nature of the experiments; the PCR 
reflects in vivo levels while the luciferase assays were done in cell culture. Only a portion 
of the region upstream of Adamts1 was included in the luciferase construct but other 
regions are relevant during transcription. The presence of these other regions may alter 
transcription of Adamts1. Overall, our data show that Tbx5 is involved in the 
transcriptional regulation of the Adamts1 gene, a regulator of the VEGF pathway. We 
have shown that a change in Tbx5 dosage can affect transcription of several trisomic 
genes, which are components of the NFAT and VEGF signaling pathways.  The links that 
we demonstrated between Tbx5 and the NFAT pathway as well as the Adamts1 gene 







Chapter 4: A universal response deficit to Sonic hedgehog (Shh) in DS and its 
possible role in CHD 
(Adapted from Currier, D.G., Polk, R.C., and Reeves, R.H. A sonic hedgehog (Shh) 
response deficit in trisomic cells may be a common denominator for multiple features of 
Down syndrome. Progress in Brain Research. 2012;197:223-36.)  
The first direct demonstration of Shh response perturbation due to trisomy came 
from analysis of cerebellar development in the Ts65Dn mouse [101]. Ts65Dn mice, like 
people with trisomy 21, have a smaller cerebellum and show specific deficits of Purkinje 
cells and of the granule cell neurons that make up the internal granule layer (IGL) of the 
cerebellum. Further, the reduced density of granule cells in the IGL of Ts65Dn mice was 
shown to occur in people with DS, as well [101]. Purkinje cells produce Shh which 
stimulates GCPs to divide and migrate inward to form the IGL [102-104]. The frequency 
of mitosis is significantly reduced in Ts65Dn, and this reduced mitotic rate is a major 
contributor to the deficit in granule cell generation in trisomic mice [105] and in DS 
[106]. Similarly, deleting a floxed Shh gene in late gestation by driving Cre expression 
with either the Pax2 or L7 promoters results in reduced cerebellar volume, 
hypocellularity and disorganization of GCPs in the external germinal layer (EGL) of the 
cerebellum  [107]. When GCPs were isolated from trisomic and euploid cerebella and 
cultured in the presence of increasing amounts of Shh, trisomic GCP responded less to 
the mitogenic effects of Shh [105].  
 These results raise the question, “Is the attenuated response to Shh in trisomic 
mice restricted to GCP, or do all Shh-responsive cells in a trisomic individual show a 




and of trisomy suggest that this mechanism may contribute to multiple DS phenotypes. 
Based on the demonstration that trisomy results in a reduced response to the mitogenic 
effects of Shh in cerebellum, the possible effects of attenuated Shh response in heart were 
considered here. We consider possible effects on heart development if the Shh 
responding cells “saw” less Shh signal as is the case for GCPs. 
 The Shh ligand is produced in cells distinct and often separated from those 
receiving the signal. Extracellular Shh-Np is sensed by the receiving cell via interactions 
with the 12-pass transmembrane protein, Patched (Ptch) [108, 109].  In the pathway-off 
state (Fig. 12a), Ptch catalyzes the production of an unidentified repressor of Smoothened 
(Smo), a 7-pass transmembrane protein with possible G-protein coupled receptor activity 
[110, 111].  When Smo is repressed (pathway-off), the transcription factors Gli2 and Gli3 
are targeted to the proteasome for processing to produce their transcriptional repressor 
forms (Gli2R, Gli3R) [112, 113]. Another pathway element, Suppressor of Fused (SuFu), 
is found in both the cytoplasm and the nucleus and interacts with Gli1 and Gli2 to further 
suppress pathway activity [114, 115]. SuFu/Gli complexes are exported from the nucleus 
and tethered in a SuFu dependent manner, in the cytoplasm.  Further, SuFu inhibits Gli 
mediated transcriptional activation by binding and inhibiting DNA-bound Gli1 or Gli2.  
The pathway is activated when Shh binds to Ptch, inhibiting the catalytic activity of the 
latter, thereby reversing the repression on Smo (Fig. 12b). This results in degradation of 
SuFu and Gli phosphorylation to produce activator Gli proteins that move to the nucleus 
and promote transcription [110, 116-118].   
 Jenkins [119] broadly defines several mechanisms for pathway activation outside 





Figure 12. The Sonic hedgehog pathway. (a) In the pathway-off state, Patched (Ptch) catalytically inhibits Smoothened (Smo) 
activity through an unidentified intermediate. Suppressor of Fused (SuFu) mediates cleavage of Gli2 and Gli3 into their repressor 
forms, lacking transactivation domains. The Gli2/3 repressors translocate to the nucleus where they repress transcription by binding 
target gene promoter sequences. (b) Shh binding to Ptch inhibits its catalytic repression of Smo, resulting in activation of Smo and 
degradation of SuFu. In the absence of SuFu, Gli2/3 are phosphorylated to become the activator forms. Gli2/3 activators translocate to 





For example, Ptch can interact directly with CyclinB1 to affect cell cycle progression 
[120] and can initiate apoptosis in neuroepithelial cells until it is blocked by Shh binding 
[121].  Although Ptch is the primary receptor for Shh, several other membrane bound 
proteins compete for Shh and are capable of enhancing or inhibiting pathway activity.  
Cell Adhesion Molecule-Related/Down-Regulated by Oncogenes (CDO), Brother of 
CDO (BOC), Growth Arrest Specific 1 (Gas1) [122],  and Hedgehog Interacting Protein 
(Hhip) [123] all interact with Shh.  Of these, expression of CDO, BOC, and Gas1 
increases Shh pathway activity, while Hhip negatively regulates the pathway  [124]. The 
Gli transcription factors can also be regulated outside of the canonical Shh pathway. 
Borycki et al demonstrated that Wnt1 and Wnt4 can induce Gli2 expression and repress 
Gli3 expression in a quail segmental plate mesoderm explant culture system [125].  
Others have suggested that Gli1 protein may be regulated independently of Shh through 
the MAPK pathway [126].     
Although much of the work regarding the Shh pathway has examined brain 
development, the pathway also plays a role in heart development. Shh is secreted from 
cells in both the pulmonary endoderm, where it is required for proper atrial septation 
[127], and in the pharyngeal endoderm, where it is necessary for proper OFT septation 
[128].  Shh signaling marks cells within the SHF as progenitors of the atrial septum and 
OFT. Labeling of hedgehog-responsive cells early in heart development demonstrates 
that those cells migrate from the SHF and contribute to the primary atrial septum, dorsal 
mesenchymal protrusion (DMP), endocardial cushions and pulmonary trunk [127].  The 




complex of the atrioventricular septum [129].  The appearance of this complex is 
necessary to complete AV septation and to anchor AV valves.  
 Neural crest cells (NCCs) of the fourth and sixth pharyngeal arches contribute to 
heart development by migrating into the OFT of the heart, contributing to septation and 
alignment.  Smo is necessary for Shh pathway activation, and the loss of this gene in 
NCC resulted in errors in septation and alignment of the aorta and pulmonary trunk, as 
well as defects in pharyngeal arch arteries [130].  NCCs contribute substantially to the 
first pharyngeal arch (PA1), and trisomic embryos have been shown to have a smaller 
PA1, which contain fewer neural crest-derived cells and these cells had a lower mitotic 
index than did their euploid counterparts [131].   Several steps in NCC delamination, 
migration and proliferation require Shh signaling. Trisomic cells isolated from PA1 
showed lower proliferation than did euploid. However, addition of Shh to the cultures 
increased cell division, bringing the rate in trisomic cells to that seen in euploid cultures 
[132]. Trisomic neural crest cells in PA1 exhibit defects in proliferation, which can be 
rescued by Shh.  If these defects extend to NCC of PA 4 and 6 then it is likely the 
reduced response to Shh is contributing to CHD in trisomy. A Shh response deficit could 
thus contribute to heart defects through direct effects in SHF, or because of an impaired 
response of trisomic neural crest. 
 In support of this idea, several mouse models with impaired Shh signaling also 
display errors in heart development (Table 6).  A knockout of Shh (Shh-/-), in which exon 
2 and its flanking introns are removed, displays AVSD and other structural defects [133, 
134].  Similarly, when Shh signaling is blocked by cyclopamine at HH stage 14 chick 




Table 6. Congenital heart defects in Sonic hedgehog pathway mutants 
Perturbation Phenotypes Age Notes Refs. 
Shh-/- 
Pharyngeal arch artery 
defects, ASD, VSD, 









Pharyngeal arch artery 
defects, PTA, AVSD E10.5 






PTA, ASD, VSD, 
AVSD, rounded and 
short AV valves 
E14.5 – 
E18.5 




Wnt1-Cre; Smoflox/- PTA E10.5 Smo ablated in neural crest  [128] 
SmoGli1-CreERT2 ASD and AVSD E13.5 
Floxed Smo allele 




ShhNkx2.1-Cre ASD E13.5 








reduced proliferation in the SHF result [135].  Analogous outcomes occur when other 
components of the pathway are altered. Conditional knockouts of Smo and Shh result in 
AVSD and PTA in mouse embryos.  Deletion of a floxed Shh allele in all cells expressing 
either Nkx2.5 or Gli1 results in AVSD [127, 128].  Thus Shh signaling mutants present 
AVSDs, VSDs, and ASDs, structural defects that are common in DS [136].      
 Septal defects were attributed primarily to errors in the endocardial cushions for 
many years, but evidence has emerged that points to a critical role for DMP as a 
contributing factor, especially to AVSD and secundum ASD [127, 130].  In this light, it is 
relevant that Shh signaling is not required for endocardial cushion contributions to 
septation, but is necessary for proper contributions to DMP from the SHF. When Shh 
signaling is disrupted in DMP progenitors or the SHF, the DMP is hypoplastic or does 
not form and an AVSD results [127, 130].  Hypoplastic DMP has also been described in 
human fetuses with DS and in mice trisomic for all of Mmu16 [129, 137, 138].  Hence, 
there is an important role for Shh signaling in formation of the DMP, and for DMP 
involvement in AVSDs; DS is the biggest major risk factor for AVSD [136].  Overall, 
there are substantial similarities between heart phenotypes caused by trisomy and those 
seen in Shh signaling mutants. These results do not prove causation but they are 
consistent with the effects expected from reduced response to Shh signaling in the 
developing heart.  
None of the genes encoding canonical Shh signaling pathway components is 
encoded on Hsa21. However, up-regulation of Ptch (resulting in down-regulation of the 
SHH pathway) has been reported in Ts65Dn mice for a specific, small group of stem cells 




In cultured neurospheres developed from the SVZ region, a C-terminal fragment of the 
APP protein, AICP, can contribute to the up-regulation of Ptch transcription [139]. Since 
the APP gene is found on Hsa21 and thus is chronically upregulated in DS (and also in 
Ts65Dn mice), this provides a possible explanation for the attenuated mitogenic response 
to Shh by trisomic cells.  
Molecular pathway analysis has implicated several additional Hsa21 genes whose 
expression may impinge on Shh signaling directly or indirectly, especially on the 
regulation of Gli1, 2 and/or 3 (reviewed in [140]). To date, however, there is no direct 
demonstration of a dosage sensitive trisomic gene disrupting Shh signaling in the 
developing heart. Trisomic mouse models of DS provide a sensitized genetic background 
for dissection of these mechanisms. Trisomy for Hsa21 results in increased dosage for 
more than 300 genes and numerous studies of gene expression in DS and in animal 
models suggest that most of these will be up-regulated by ~50% whenever and wherever 
they are normally expressed. The availability of segmental trisomies in animal models 
that recreate the dosage imbalances seen in DS and the demonstration that this produces 
features analogous to those in DS [141] has led to a productive phenotype-based 
approach to the development of therapies [141-143]. 
 The phenotype-based approach suggests the possibility that multiple effects of 
trisomy in different tissues may result from perturbations in the same developmental 
pathways and regulatory processes, as posited here for Shh. A deficit in response to the 
mitogenic effects of Shh has been demonstrated in trisomic cerebellar GCP. Trisomic 




counterparts. A similar response deficit in other trisomic cell types could affect 




Chapter 5: Conclusions 
Trisomy 21 is a destabilizing condition. Many features of the syndrome are 
present in all individuals with trisomy 21, such as cognitive impairment and craniofacial 
dysmorphology; but it is not the cause of many other features, such as CHD.  The 
absence of 70+ features in many individuals with DS is indication that DS is a major 
destabilizing factor in development but not the sole cause of many of the associated 
developmental errors. Evidence of the damaging effect of trisomy on heart development 
has been provided here.  
Combining trisomy with haploinsufficiency for the Tbx5 gene caused a dramatic 
increase in the appearance of a rare defect, OA.  Tbx5+/- mice have an 18% incidence of 
OA, while Ts65Dn mice show a 17% frequency of defects affecting the great vessels 
[36]. Combining trisomy with a reduced dosage of Tbx5 exacerbated the OA phenotype, 
resulting in 58% of Ts, Tbx5+/- mice having an OA. The combination of trisomy and 
reduced Tbx5 dosage caused a dramatic increase in CHD, beyond what was seen when 
either factor was present alone. As mentioned in chapter 1, people with DS and mutations 
in TBX5 show similarities in CHD with Ts, Tbx5+/- mice [66]. Both present with OA and 
many other defects. Similar insults in mice and humans show the usefulness of the 
Ts65Dn mouse model for the study of the genetics behind heart development. Analogous 
defects in mice and humans suggest that the molecular pathways involved in heart 
development are also comparable between these species.   
Due to the large number of genes at dosage imbalance in trisomy, it is not 
surprising that multiple pathways are affected. We can begin to investigate the genetics 




genetic pathways that are critical to heart development are affected when trisomy and 
Tbx5 haploinsuffiency are combined. The basis for the effect is complex. A change in 
Tbx5 dosage can affect transcription of Adamts1, Dyrk1a, and Rcan1, genes that are 
components of the NFAT and VEGF signaling pathways.  Both pathways can be 
regulated by trisomic genes and are essential for proper heart development. The parallels 
between DS and Ts6Dn suggest that these pathways may also play a role in the 
development of CHD in people with DS. In fact, other studies have already shown links 
between DS-associated AVSD and components of the VEGF pathway [25] (Redig, J.K., 
G.T. Fouad, D. Babcock, B. Reshey, E. Feingold, R.H. Reeves, C.L. Maslen, Allelic 
Interaction between CRELD1 and VEGFA in the pathogenesis of cardiac atrioventricular 
septal defects, AIMS Genetics, in press). Our findings document previously unknown 
connections between Tbx5 and trisomic genes. We provide evidence of the usefulness of 
examining the impact of heart development mutations on a trisomic background to 
further understand the possible role of pathways in heart development. 
Not only has this study provided evidence of the usefulness of the trisomic 
condition in studying the genetics of heart development it has also provided evidence of 
novel roles for both trisomy and Tbx5 in heart development.  The increased incidence of 
OA in Ts, Tbx5+/- mice suggest a role for both genetic insults in development of the OFT. 
Prior to this study defects in aortic alignment had not been seen in Tbx5 mutants. OA has 
been identified in individuals with DS but only as a component of Tetralogy of Fallot.  
Pitx2 expression is reduced on the Ts, Tbx5+/- background, and this could contribute to 
defects in the left-right asymmetry of the heart in these mice. Neither atrial isomerism nor 




previously. Putting Tbx5+/- on a trisomic background revealed an effect on left-right 
patterning. Destabilization induced by trisomy most likely results in a subclinical defect 
that exacerbates defects caused by reduced dosage of Tbx5.  
While the mechanism for the increase in OA in Ts, Tbx5+/- mice is unknown, 
further study of the Ts65Dn mice could lead to the discovery of that mechanism. 
Evidence has been found linking Tbx5 dosage to the Shh pathway. Tbx5 is expressed in 
hedgehog responsive atrial septum progenitors, and ASDs in mice haploinsufficient for 
Tbx5 were rescued by constitutive Shh signaling in the SHF [57]. As mentioned in 
Chapter 4, a universal response deficit to Shh in trisomic cells could be part of the 
mechanism behind the defects described here.  The combinatory effect of reduced dosage 
of Tbx5 and a reduced response to Shh signaling may lead to a further reduction in Shh 
signaling than either trisomy or Tbx5 haploinsufficiency alone.  Although the resulting 
defects described here and in the aforementioned study are not the same, the mechanism 
posited can still explain both defects.  In the study by Xie et al. [57] the reduction of Tbx5 
dosage and the subsequent activation of the Shh pathway were specific to the SHF.  The 
genetic insults in the Ts, Tbx5+/- mice were universal, affecting all cell types.  An effect 
on Shh signaling in all cell types, rather than just the SHF, could explain the difference in 
defects in the two studies. 
The OFT is the precursor to the aorta and pulmonary artery during development.  
It comprises distinct cell lineages: the primary heart field, the secondary heart field and 
the cardiac neural crest.  Proper development of the OFT requires the cooperation of all 
these different regions.  The cardiac neural crest cells migrate from pharyngeal arches 4 




Previous work in our lab has shown that Ts65Dn mice have a reduced number of cranial 
neural crest cells in pharyngeal arches 1 and 2, as well as deficits in delamination, 
mitosis, and migration due to a decreased response to Shh [131].  Similar deficits in the 
cardiac neural crest cells might contribute to the appearance of OFT defects in these 
mice. A reduced dosage of Tbx5 in these hedgehog responsive cells may exacerbate the 
phenotypes described. Tbx5 expression is an early marker of myocyte lineage.  When 
cells from the secondary heart field begin to colonize the OFT, Tbx5 is up-regulated, 
beginning the process of cardiomyocyte differentiation.  Defects in the development of 
cardiomyocytes in the OFT are believed to lead to alignment defects [144].  Insufficiency 
of Tbx5 hinders development of cardiomyocytes, thus affecting the formation of the 
OFT.   
The combination of Tbx5 haploinsufficiency and a reduced response to Shh in 
trisomy may begin earlier in development than at the colonization of the OFT.  In studies 
of the chick, Pitx2 was induced by Shh very early in development. When an anti-Shh 
antibody was added to the left side of HH stage 5 chick embryos Pitx2 expression was 
blocked in the lateral plate mesoderm, leading to laterality defects later in development 
[145]. Shh signaling is needed for proper expression of Pitx2. While no direct link has 
been found between Tbx5 and Pitx2 in the heart, connections between the two genes have 
been shown in another organ.  Pitx2 represses Tbx5 in the abdominal wall of E10.5 
mouse embryos [62]. If both reduced Tbx5 dosage and a universal response deficit to Shh 





The results reported here also remind us of the complexity of heart development, 
and of the coordination that must occur during this process.  For example, ventricular 
septation requires not only the proper formation of the ventricular septum but also the 
endocardial cushions, the DMP, and other structures in the heart. A defect in any one of 
them could lead to improper septation. All of the different processes in the heart (i.e. 
chamber formation, septation, etc.) must coordinate with each other for proper heart 
formation.  Tbx5 is known to affect ventricular and atrial septation and Pitx2 affects atrial 
development, yet the Ts, Tbx5+/- mice have an increase in defects of aortic alignment. 
These results show that atrial and ventricular development have an influence on aortic 
alignment. During embryological development all of the different processes that take 
place in the heart are working in conjunction and rely on each other for proper 
development. 
DS is a leading risk factor for CHD, and clearly a destabilizing factor during 
development. Gene dosage imbalance as a result of trisomy has effects on Shh signaling, 
which interacts with other modifiers as well. The Ts65Dn mouse model shows 
phenotypes similar to those seen in DS, and provides an excellent model for studying 
genetic modifiers of CHD, both trisomic and disomic.   The trisomic population is 
extremely useful for gaining a deeper understanding of heart development and CHD. 
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